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Abstract 
Herceptin was the poster child of personalized medicine that brought forward the notion 
that contemporaneously developed companion diagnostics (CDx) could lead to more 
efficacious use of a cancer therapeutic in a selected population. Despite a gap of 12 years, 
the recent approvals of Zelboraf and Xalkori in quick succession by the FDA are a testament 
to the fact that the age of cancer therapeutics co-developed with a companion diagnostic is 
finally upon us.  
The purpose of this thesis was to test the hypotheses, that the trend for CDx based therapy 
launches in oncology is NOT headed towards a dramatic upturn in the next 5 years and in 
the view of biopharmaceutical executives – increasing price and market share of launched 
drugs are the dominant drivers for investing in companion diagnostics, and that the other 
features of CDx, such as improving the productivity of oncology drug development and 
reducing development costs are essentially dispensable. 
These hypotheses were tested using a study design that involved conducting a pilot study 
comprising of 18 interviews of stakeholders directly involved with the decision making of 
oncology drug development – to synthesize the extent of contemporaneously developed 
CDx to be launched with a cancer therapeutic in the coming 5 years. 
An analysis of the results obtained from the survey indicate, that a significant number of 
oncology drug launches within this decade would feature a co-developed companion 
diagnostic, and that despite challenges and initial trepidations over this business model – 
the higher probability of success, lower development costs, shorter time to market and 
pricing power associated with this approach, are incentives that are increasingly attracting 
more oncology firms to adopt this strategy for developing targeted therapeutics. Based on 
these findings, the original hypotheses were rejected. 
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5 
1. Background 
Herceptin was the first successful anticancer therapeutic approved by the Food and 
Drug Administration in 1998 for the treatment of HER2-positive metastatic breast 
cancer1. More importantly, Herceptin was also the first clinically adopted step 
towards personalized medicine in oncology2, whose approval – it was predicted, 
would usher in a new era of cancer drug development, where biomarker (BM) based 
drug discovery and development programs, as well as co-development of 
companion diagnostics (CDx), would become the norm3.  
 
However in the last 12 years4 since Herceptin’s launch, there have been only a 
handful of examples (Appendix A) where oncology drugs have been launched with 
a contemporaneously developed companion diagnostic5. Why? 
 
                                                        
1 US Food and Drug Administration, Table of valid genomic biomarkers in the context of approved drug labels, Available at: 
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm Accessed Aug 13, 2011 
2 Piccart-Gebhart et al. (2005) and Romond et al. (2005) 
3 Ginsburg, G.S. and McCarthy, J.J. (2001) TRENDS in Biotechnology Vol.19 No.12 December 2001, 491-496 
4 CenterWatch, FDA Approved Drug Therapies in Oncology, available at: http://www.centerwatch.com/drug-information/fda-
approvals/drug-areas.aspx?AreaID=12 Accessed Aug 13, 2011 
5 Cohen, J., Tufts CSDD Report, Volume 13, Number 4, Page 2, July/August 2011 
28 
26 
21 
4 
7 
2 
5 4 
0 
2 
0
5
10
15
20
25
30
1995 - 1999 2000 - 2004 2005 - 2009 2010 2011
Figure 1: Oncology Drugs & CDx Launches (1995 - 2011) 
# Oncology Drugs Launched # Drugs in market with a CDx
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2. Literature review 
The sequencing of the human genome more than a decade ago was expected to drive 
rapid advancement in the understanding of cancer biology and herald the age of 
personalized medicine. While the subsequent years have seen many false starts and 
false hopes, the age of personalized medicine now appears to be upon us6. The 
advances in genomic and proteomic science have led to the development of 
“targeted” diagnostics and therapeutics that leverage knowledge of a specific 
cancer’s genetic makeup to create a more personalized approach to medicine. The 
overall diagnostic and therapeutic market – comprised primarily of pharmaceutical, 
medical device and diagnostics companies – estimated at $24 billion in 2009, and 
growing by 10% annually, is projected to reach $42 billion by 20157.  
 
While the development of recombinant DNA technology may have been a 
prerequisite for the emergence of today’s biopharmaceutical giants such as Amgen 
and Genentech, others believe that the key enabler was the U.S. Orphan Drug Act of 
1983 which gave valuable market protection to the first product reaching the 
market for indications where the market was small8. In contrast, the expectation 
that biomarker driven patient selection reduces the target market size for 
oncology drugs has kept the largest biopharmaceutical companies, and by extension 
diagnostics companies at an arm’s length from employing a targeted approach to 
oncology drug development.  
                                                        
6 McDougall, G, and Rosamond, M., Personalized medicine - What it means for patient-centered healthcare and how to address 
its current challenges, PwC View issue 13, 2010 
7 McDougall et al (2009), The new science of personalized medicine, PwC Oct 2009 
8 Probst et al. (2009) Diagnostics 2009: Moving towards personalized medicine, PwC Oct 2009 
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However, there are several factors today that are accelerating the growth of 
personalized medicine – on one hand there is the recent passage of U.S. Health 
Reform, with its focus on reducing redundancy and waste in healthcare, as well as 
cutting drug costs, and on the other hand there’s the desire of payers to reduce costs 
in the long term by providing precise diagnostics required to avoid unnecessary or 
ineffective treatments, prevent adverse events, develop prevention strategies and 
essentially deliver more effective, targeted therapeutics at an optimal cost. Hence, 
faced with looming patent expiries of current blockbusters in a changing healthcare 
environment, the biopharmaceutical industry is showing a renewed interest in 
the potential of ‘nichebusters’ – drugs targeted to small populations but 
commanding a premium price – to replace some of the lost income9.  
In the last few years, biopharmaceutical companies have become 
increasingly interested in biomarkers for maximizing the economic potential of 
their assets, and more recently have been incorporating them into drug 
development programs for their eventual co-development as a CDx associated with 
their targeted therapies. For the physicians and patients, the promise of CDx lies in 
the ability of the assays to assist in making more informed treatment 
decisions10. Typically, a CDx is used to enhance the efficacy and, or safety of a 
specific drug by targeting a specific group of patients. For the drug developers, co-
development of CDx alters the process of drug development and commercialization 
of drug candidates, which can yield safer drugs or drugs with enhanced efficacy in a 
                                                        
9 McDougall, G., Competing in an Era of Personalized Medicine, Drug Discovery, Delivery & Therapeutics, 2009 
10 Emerging Trends in Drug Development: Companion Diagnostics-9th Forum, 
http://sabpa.org/photos/SciForum11/S&T_2011_Report.htm Accessed on Aug 7, 2011   
  
 
8 
faster, more cost-effective manner11. In essence, co-development of a CDx can not 
only reduce the time it might take for a novel therapeutic to complete its bench to 
bedside journey, it may save billions of dollars as well as avoid unnecessary 
treatments and potential side-effects for individuals with life-threatening diseases.  
Despite all the espoused benefits of associated biomarkers and companion 
diagnostics to regulators, payers, physicians, patients and drug developers, when 
Research & Development executives at 16 of the top 20 biopharmaceutical 
companies were interviewed in a survey by McKinsey in mid-2008, they indicated 
that while 30–50% of drugs in development had an associated biomarker 
program, fewer than 10% of these drugs were expected to be launched with a 
companion diagnostic over the next 5–10 years12. The research further suggested 
that for the pharmaceutical and biotechnology companies, the utility of companion 
diagnostics was exponentially more in the post launch phase of the drug – for 
generating greater value after marketing by increasing price and market share, than 
for improving productivity during the development phases of the drug13.  
That said, much has changed in the recent years – more than ever drug 
developers recognize that opportunity exists in lower prevalence tumors where 
unmet need is high or in higher prevalence tumors within specific sub‐populations. 
Coupled with late-stage failures of high profile candidates (e.g. Iniparib, Zebotentan) 
and emerging pricing risks in developed markets (e.g. Velcade) the trend in 
oncology drug development seems to be shifting towards ‘smaller bets placed wisely’.      
                                                        
11 Phillips KA, Bebber S, Issa A. Diagnostics and biomarker development: priming the pipeline. Nature Reviews Drug Discovery 
(2006) 5,463-469   
12 Ma et al. (2009) The microeconomics of personalized medicine: Today’s challenge and tomorrow’s promise, Nature Reviews 
Drug Discovery Vol. 8 April 2009, 279 - 286 
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3. Thesis Objective 
In this study I hypothesize that – despite the increased focus on personalized 
medicine – firstly, the trend for CDx based therapy launches in oncology is NOT 
headed towards a dramatic upturn in the next 5 years and secondly, in the view 
of pharmaceutical executives increasing price and market share of launched drugs 
are the dominant drivers14 for investing in companion diagnostics, and that the 
other features of CDx, such as improving the productivity of oncology drug 
development and reducing development costs are essentially dispensable.  
 
  
                                                        
14 Ma et al. (2009) The microeconomics of personalized medicine: Today’s challenge and tomorrow’s promise, Nature Reviews 
Drug Discovery Vol. 8 April 2009, 279 - 286  
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4. Methodology 
To gain a perspective on the use of associated biomarkers in the current oncology 
drug development environment and to gauge the potential of companion diagnostic 
based therapy launches in the next 5 years, I performed 18 interviews in the 
summer of 2011 with executives and key opinion leaders from leading oncology 
companies, consulting firms and venture capital funds.  
 
The interviews had a dual approach for testing the hypothesis – quantitatively, 
study the pipelines of a diverse range of oncology companies with drug candidates 
at various stages of development, to approximate if CDx associated drug launches 
could exceed the current trend by at least 100% i.e. could double in the next 5 years, 
and – qualitatively, explore the thinking and rationale behind the drug development 
strategies of these firms, to appreciate if pricing and market share were the top 
drivers for CDx investments.  
 
4.1 Questionnaire Design 
Armed with the knowledge gained from my review of the existing literature, I 
designed an interview questionnaire to elucidate the following: 
 Experience and exposure of interviewees to oncology drug development  
 Oncology pipeline of participating companies and their current approach to 
drug launches in the next 5 years – with or without a companion diagnostic 
 Strategic approach to associated biomarkers in current oncology drug 
discovery and development environment 
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 Co-development strategy for companion diagnostics within the company’s 
active oncology drug development programs 
 Key challenges to the development and acceptance of personalized medicine 
within oncology firms and actions required to overcome them 
 
4.2 Participant Selection 
Aiming to keep the study outcome unbiased, and to appreciate the perspective of 
oncology drug development firms in various stages of maturity, I selected 
participating companies across the entire spectrum of drug developers – from 
newly launched venture funded oncology firms to small companies with drug 
candidates in phase I, and from medium sized companies with at least one launched 
oncology drug to organizations with the largest portfolios of oncology drugs in the 
world. In addition, the participant selection was driven by an ambition to learn 
from, and synthesize the impressions of executives who were directly responsible 
for deciding the drug development strategy of an oncology company. 
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5. Interviews Questions – Rationale, results and discussion 
Almost 80% of the interviews were conducted in face-to-face meetings lasting over 
45 minutes, the rest were via teleconferences. Given below are the questions – with 
their rationale and a summary of findings consolidated from the responses of all 
interviewees. Please note, the questions were asked chronologically as 
illustrated in the questionnaire (Appendix B) but are presented here in 
context of their relevance to the implied sub-topics within the interviews.  
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5.1 Experience & Exposure 
Question #1: 
How long have you been associated with commercialization of oncology products, 
and in what roles? 
Rationale 
The primary objective was to isolate the oncology drug development experience of 
the interviewees from their other life sciences careers. The secondary objective was 
to ascertain if their current roles were directly associated with the decision making 
of oncology drug development strategy within oncology companies. 
Results 
56% of the interviewees had been associated with oncology drug development since 
Herceptin’s approval in 1998, and 78% had witnessed the evolving success story of 
Gleevec, from its approval in 2001 for BCR-ABL positive Chronic Myelogenous 
Leukemia patients to 2011 – where it is currently approved for 9 indications15.  
 
                                                        
15 Gleevec: Package Insert http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf Accessed on Sep 3, 2011   
22% 
22% 45% 
11% 
Figure 2: Interviewees Experience - Oncology  Drug Development 
5-10 years 10-15 years 15-20 years >20 years
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Further, resulting from a conscious effort to reach out to the decision makers of 
drug development strategy within participating companies, 75% percent of the 
interviewees were senior executives within their organizations.  
 
The venture fund partners were past executives of biopharmaceutical firms and 
were currently involved with oncology drug development startups in Cambridge, 
Massachusetts. A full list of participants and their companies is attached as 
Appendix C.  
Discussion 
In essence, the study participants were well versed with the intricacies and 
challenges of CDx associated oncology drug development, and the impact of 
companion diagnostics in the success of a targeted therapeutic.  
 
CEO 
33% 
CMO 
11% CSO 
22% 
CCO 
11% 
VC 
11% 
Consultant 
11% 
Figure 3: Interviewees Roles - Oncology Drug Development  
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Question #2: 
How many oncology drug development projects and launches have you been 
involved with? Of those, how many had an associated BM during drug development 
and how many were actually launched with a CDx? 
Rationale 
The purpose of this question was to establish the actual hands on experience of the 
participants in developing biomarker driven oncology drugs and, or co-development 
of companion diagnostics. 
Results 
Put together, the participants had played a decision making role in the development 
of 389 New Chemical Entities (NCE) in oncology, of which 70 projects had involved 
an associated predictive biomarker during any stage of the drug’s development. 
Further, between them the interviewees had seen through 56 oncology drug 
launches during the course of their careers, of which 9 drugs have – at least 
one associated CDx with it, on the market today.    
 
389 
70 56 
9 
0
50
100
150
200
250
300
350
400
450
# Projects # Associated BM # Launches # Launch has CDx
Figure 4: Interviewees Exposure - Oncology Drug Launches 
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Discussion 
Given, at the time of writing this report, there have been at least 86 oncology drugs16  
launches since 1995, and of them at least 13 drugs have a companion diagnostic17 
available today, the cumulative experience of the interviewees accounted for 65% of 
all oncology drugs launched and for 69% of all oncology drugs available in the 
market today together with one or more companion diagnostic. Moreover, a quarter 
of all the drug development projects that the interviewees had been involved with, 
had an associated biomarker strategy during the development.  
 
Question #3: 
What is your company’s approximate annual revenue from oncology products? Also, 
what’s your approximate annual R&D budget within oncology? 
Rationale 
The goal of this question was to ascertain the revenue range of companies 
represented by the interviewee pool, and to appreciate the participating companies 
focus on developing oncology therapeutics, based on the level of resources 
committed to oncology research and development.   
Results 
Based on information provided, around half of the participating firms were oncology 
early stage firms and at present did not have any revenues. The revenues for few of 
the participating large firms are given below: 
                                                        
16 CenterWatch, FDA Approved Drug Therapies in Oncology, available at: http://www.centerwatch.com/drug-
information/fda-approvals/drug-areas.aspx?AreaID=12 Accessed Aug 13, 2011 
17 Cohen, J., Tufts CSDD Report, Volume 13, Number 4, Page 2, July/August 2011 
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Table 1 - Annual Revenues of Top Global Oncology Franchises18 ($47.2bn) 
Companies Revenue ($bn) %MS Rank 
Roche $16.52 35% 1 
Novartis $5.19 11% 2 
Sanofi $3.78 8% 3 
Lilly $3.78 8% 4 
AstraZeneca $3.78 8% 5 
Pfizer $1.89 4% 6 
Takeda $1.42 3% 7 
MSD $0.94 2% 8 
BMS $0.94 2% 9 
J&J $0.94 2% 10 
All Others $8.02 17%   
  
The oncology revenues and research budgets for Roche and Genentech are 
combined, so are for Sanofi and Genzyme. While, GlaxoSmithKline and Bayer were 
represented in the research, their oncology revenues are not mentioned here, 
although their R&D budgets are illustrated below, with the budgets of other 
oncology drug development firms.  
 
                                                        
18 IMS Health MIDAS MAT December 2010. Oncology defined as L1&L2 
Forma Agios Epizyme Aveo Infinity 
Bayer GSK Takeda 
Sanofi 
Novartis 
Roche 
0
1000
2000
3000
4000
5000
6000
Figure 5: Interviewees Firms' R&D Budgets - ($ Million) 
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Discussion 
The annual R&D budgets of the mid to large sized oncology companies varied 
significantly, and for many companies did not exactly coincide with their relative 
size of oncology revenues, which points towards the optimism and commitment of 
the participating firms towards oncology as a lucrative therapy area in the future. 
The inclusion of several oncology startups in the study was deliberate, owing to the 
recent strategies of large biopharmaceuticals companies to look for external drug 
candidates for building their future pipeline19, and the corroborating growth of in-
licensing and partnerships deals20 within in the recent years, which suggest that the 
pipeline strategy for large firms is shifting from ‘research’ to ‘search’ – where, 
a dollar invested in in-licensed compounds is expected to deliver 3 times as 
much value as compared to a dollar invested in in-house research21. 
  
                                                        
19 Donnelly, J.M., Sanofi Chief details innovation strategy, Boston Business Journal Available at: 
http://www.bizjournals.com/boston/news/2011/04/12/sanofi-chief-details-innovation-strategy.html  Accessed Sep 3, 2011 
20 CurrentPartnering, Partnering Agreements in Pharma and Biotech Yearbook 2010, January 2011 
21 Morgan Stanley Pharmaceuticals Report, January, 2010 
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5.2 Current Strategy – Oncology Pipeline  
Question #4: 
Please complete the following about your current oncology pipeline products: 
a. The number of drugs currently in development, across various phases? 
b. Of those, the number of drugs that have an associated BM? 
c. Of those, the numbers that currently have a CDx co-development program? 
Rationale 
The intention was to gain an understanding of the current strategic approach of 
oncology companies related to biomarker use in drug discovery and development. 
Results 
Whereas the number of oncology drugs in development across all participating 
firms, from 71 NCEs in preclinical stage gets reduced to 25 in phase III, the 
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proportion of drugs in development that currently have a biomarker associated with 
it remains fairly stable, from 58% in preclinical to 48% in phase III. Moreover, the 
number of associated biomarkers being developed with the intent of launching them 
as a contemporaneously developed CDx remains fairly constant as well, from 38% in 
preclinical stages to 36% in phase III, except for a phase II dip to 24%. 
Discussion 
A significant percentage of oncology drug development programs today, are 
utilizing biomarkers right from the stages of initial discovery and target selection. 
However, it is also clear that the predominant use of biomarkers in discovery does 
not translate into an equal number of predictive biomarker programs throughout 
development. It’s interesting to note that although drugs in the initial phases (I & II) 
have nearly a similar proportion of biomarkers featured in the development 
programs, in phase III the number of programs featuring biomarkers drops.  
This first key observation can be understood in light of the growing uses of 
biomarkers from markers of drug efficacy, to monitors of treatment effectiveness, 
drug toxicity and development of resistance – all of which allows a drug developer 
to utilize biomarkers at different stages of development. Given, an associated 
biomarker is not considered a requirement for a compound to move into clinical 
development22, unless a biomarker has the potential to either assist with 
positive or negative selection of patients, or act as a surrogate endpoint in 
clinical trials, its ongoing use in phase III studies may be limited. A number of 
interviewees in the study acknowledged that although inclusion of an associated 
                                                        
22 Tufts CSDD Impact Report  Volume 12, Number 6 • November/December 2010 
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biomarker from the preclinical stages is ideal, in some cases biomarkers may enter 
the development program as late as Phase III. 
The second key observation from this question pertains to the proportionate 
rise in the number of companion diagnostic programs being co-developed in phase 
III compared to phase II, which indicates that selection of the right patient 
population prior to approval and launch is becoming intrinsic to oncology drug 
development strategy, and that there is some level of positive selection for 
taking drugs with a potential CDx into phase III. 
In totality, the proportionate number of biomarker programs and CDx in late 
stage development, when compared to currently marketed drugs, refutes the 
hypothesis and instead suggest that a significant number of drug launches in the 
next five years may actually have a contemporaneously developed companion 
diagnostic associated with it. 
 
Question 7: 
Of the drugs in your pipeline with an associated BM, in your view, how many: 
- Are likely to be launched in the next 5 years? 
- What would be the expected position-in-class at launch? 
- Also, of those how many would be launched with an associated CDx? 
Rationale 
Central to testing my hypothesis, the question’s aim was to appreciate the likely 
number of CDx associated oncology drug launches from the participating companies 
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in the next 5 years, and also to understand if the launch position influenced the 
decision to launch with or without a companion diagnostic.  
Results 
In the next 5 years, the participants expect their companies to launch 34 oncology 
drugs put together, of which 20 drugs are likely to be launched with a 
contemporaneously developed CDx, with most launches being either first or second 
in class.    
Discussion 
Right from the inception of the analysis the focus was on drawing conclusions based 
on a developer’s strategic intent and preparation to launch, and not on referencing it 
with FDA’s oncology drug approval rate to arrive at an accurate number of launches. 
 
In all, the study participants’ companies had 189 drugs in development, of which 
56% had an associated biomarker, and based on their strategic approach to clinical 
trials and the current data emanating from their drugs, the developers were 
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confident that 34 of those could become approved therapies in the next 5 years. 
More importantly, the fact that 59% of those potential launches are expected to be 
with a CDx – indicates that a significant number of CDx associated drug launches in 
oncology are to be witnessed in the coming years, which does not agree with my 
hypothesis. 
Also, considering that the participating companies in the study 
cumulatively represented in excess of 60% of the global oncology revenues23, 
the impact of their pipelines on the future of oncology launches cannot be ignored. 
Hence, a comparison of the number of expected launches from the participating 
firms with the past oncology drug launches across the industry, point towards a 
major shift in CDx associated drug launches in the coming years – which 
emphatically refutes the hypothesis. 
 
                                                        
23 IMS Health MIDAS MAT December 2010. Oncology defined as L1&L2 
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This finding confirms that in the next 5 years, the trend for the proportion of 
companion diagnostic based drug launches in oncology – is indeed headed towards 
a dramatic upturn. 
The core assumption for the next part of this question was that the launch 
position of a drug points towards the intent of the developer in employing a 
companion diagnostic for their drug, at the time of launch. Based on that 
assumption, it was interesting to note that in the next five years a large majority 
of oncology drug launches with a companion diagnostic are expected to be 
either 1st or 2nd in class, which indicates that the strategic intent of the developers 
today is more focused at launching their drugs within a targeted population right 
from the start, than maximizing revenues by launching to as broad a population as 
possible, with little emphasis on the extent of efficacy in different patients. 
 
Hence, only a small percentage of CDx associated drug launches are expected to be 
utilized in capturing market share from existing players in a class. 
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Question 13: 
What in your view is the approximate cost of bringing an oncology drug to market? 
Of that, what percentage is the additional cost of co-developing a BM? In essence, 
what is the total cost of bringing an oncology drug with a CDx to market? 
Rationale 
The aim of this question was to ascertain if the cost of co-developing and launching 
a CDx was a factor in determining, whether a drug gets launched with a CDx or not. 
Results 
Based on the responses received, the cost of developing and launching an oncology 
drug ranged from $120-350million, and averaged at $260million. The cost of 
developing the drug with an associated biomarker ranged from $132-380million, 
albeit the average was only $256million, and added to that the cost of further 
developing and launching the biomarker as a CDx, increased the overall cost to 
$150-400million, with an average of $290million.    
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Discussion 
Excluding the cost of failures and the time value of money, there was general 
consensus among the interviewees that the overall cost of developing and 
launching an oncology drug hovered around $260million. Additionally, most 
interviewees were of the view that the use of biomarkers during the development 
phases had the potential to reduce this overall cost, even though just marginally. 
Moreover, considering the dismal outlook of the current reimbursement 
environment for companion diagnostics, in the perspective of the interviewees the 
cost of launching a drug with a CDx was certainly higher. Although it was not 
considered as significant in the grand scheme of a successful oncology drug launch, 
where an optimally priced drug for a selected patient population usually has the 
potential to recoup the additional cost of co-developing and launching of its 
companion diagnostic.       
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5.3 Biomarker Strategy – Oncology Drug Development 
Question 5:  
Of the drugs in your pipeline with an associated BM, at what stage of their drug 
development was the decision to invest in their BM development implemented? 
Rationale 
Considering that commencement of an associated biomarker program later than 
Phase I, makes it harder for the biomarker to be included in trials that may allow for 
its co-labeling on the therapeutic24 - this question was meant to unearth the extent 
to which biomarkers today are being used for improving development productivity. 
Results 
The data collected shows that for all oncology drugs with an associated predictive 
biomarker in various stages of development, the decision to invest in their 
biomarker programs was predominantly initiated in the early stages of drug 
discovery and development: 78% in preclinical, 14% in phase I and 6% in phase II. 
 
                                                        
24 Blair E (2004), Surrogates & diagnostics in today's pharmaceutical development. Caxton, UK: Integrated 
Medicines Ltd. 
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Discussion 
More importantly though, the data also indicate that for oncology drugs with an 
associated biomarker program in Phase II and III of development (Figure 6), the 
decision to invest in their biomarkers was made early on, therefore the strategic 
intent of the developers for using biomarkers was to improve development 
productivity and to positively impact the performance of their drugs in the 
later stages of clinical trials. Thus, the finding appears to falsify my hypothesis.          
 
Question 6:  
What drove the investment timing in these BM development decisions?  
Rationale 
Understanding the reasoning behind biomarker investments in oncology drug 
development was the second part of my hypothesis. Hence, this question was meant 
to appreciate how important was increasing price and market share of drugs to the 
drug developers, and if improvement of discovery and development productivity 
had a significant role.  The interviewees were asked to rank the reasons that drove 
their investment decisions for co-developing a predictive biomarker. 
Results  
Consolidation of all rankings indicate that increasing speed to market and 
improving go/no-go decisions were the two highest ranked reasons for investing in 
an associated biomarker program. The next tier of key drivers were establishing the 
cost vs. benefit of drug candidates early on, reduce patient attrition during trials and 
decreasing the size of clinical trials. 
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Discussion 
Quite unanimously, the interviewees pointed out that the single most important 
use of an associated biomarker program was to enhance the probability of 
success for their drug in development, approval and launch. They reasoned that 
in the background of high Phase III failures rates for oncology therapies, coupled 
with a more conservative FDA approval process, the most important consideration 
for drug developers today was improving the chances of their drug’s launch, 
translated which meant having a more productive discovery and development 
program. A few interviewees also spoke about the upcoming challenges in the 
reimbursement environment, where the idea of “pay-for-performance” in 
oncology was beginning to take hold. Payers, they said, are no longer willing to 
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Enhance Market Share
Clinical Need for a Companion Diagnostic
Support Higher Drug Prices
Decrease Trial Size
Reduce Patient Attrition
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Figure 12: Ranking of Decision Drivers - Biomarker Investment Strategy  
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pay for drugs that just work 10% of the time, and regulators were challenging 
improved progression free survival rates as clinical benefit, and instead were 
seeking to see significant improvements in overall survival rates. Premium pricing 
in oncology drugs, they thought was still possible, as long as the therapy 
provoked a remarkable improvement in the condition of a well-defined 
patient population. To sum it up, the interviewees were more interested in using 
biomarkers for increasing the efficiency and the overall number of successful 
launches, than adding value to their franchises by price increases and market share 
capturing strategies. 
 
Question 11: 
Would you take a candidate forward, in absence of an associated biomarker, and 
under what circumstances? Please explain briefly. 
Rationale 
The purpose of this question was to understand the extent to which the use of 
biomarkers is assumed as critical to oncology drug development. 
Results 
The breadth of responses to this question can be best observed by reviewing some 
of the actual replies – a selection is given below: 
Large biopharmaceutical executives: 
- “Yes of course! This is cancer we are talking about – as long as our drug can 
increase the overall survival rate, we will launch it” 
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-  “If the efficacy and safety profile of the drug is interesting, we will proceed – 
BM or not” 
-  “You can’t always find a biomarker, as long as the NPV is positive we 
continue moving forward” 
- “Absolutely, you need to be opportunistic – as long as the drug can target a 
well-defined population, you don’t always need a biomarker to personalize a 
therapeutic” 
Small biotechnology executives: 
- “No, not in oncology at least – today CDx are a must” 
- “Not really, without the knowledge of MOA it’s very hard to assure a 
thumping success in phase III trials” 
- “Yes, if the response rate is at least >30%, however if a biomarker increases 
it to >70%, then we will prefer to wait and co-develop” 
- “Yes, if my drug targets a genuine unmet need. In some cases, any response is 
better than none – of course, awareness of pharmacological properties and 
MOA always helps. Our focus is to continuously model our drug’s success, 
right until launch, and launch only if makes business sense” 
Discussion 
Despite the fact that currently a majority of oncology drugs are launched in absence 
of an associated biomarker as a CDx, many interviewees felt that today we are at 
an inflection point in terms of biomarker use in late stage clinical trials and 
their ultimate launch as co-developed diagnostics. Most also felt strongly about 
oncology as a therapy area where using a biomarker based development strategy 
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was crucial to success. The overall impression was that although efficacy, safety and 
commercial potential of a therapy, with or without a biomarker, were the primary 
considerations in a launch strategy – the knowledge of the drug’s mechanism of 
action, its pharmacological properties and the identity of the group of patients it 
benefited most, greatly enhanced its chances of approval and launch success.  
According to interviewees, even in the absence of a biomarker, the core 
principle of selecting and catering to the patient population that best 
responds to a drug, stands. Therefore, in a situation where in absence of a 
biomarker a drug’s response rate was 30% in a relatively undefined population, and 
was 70% in a stratified population with a biomarker, developers preferred to launch 
in the smaller but more responsive patient group, albeit with premium pricing. 
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5.4 Companion Diagnostic Strategy 
Question 8: 
Of the drugs in your pipeline that have an established associated CDx program, at 
what stage of their BM development was the decision to invest in a CDx made? 
Rationale 
Considering that not all associated biomarkers are co-developed as CDx (Figure 6), 
the aim here was to identify the extent to which the decision to co-develop a 
biomarker into a CDx were being taken in the later stages of drug development – 
where the decisions are more often driven by pricing and market share concerns, 
than for enhancing the clinical performance of a therapeutic. 
Results 
Inferring from the participating firms data, for 72% of the oncology drugs with a 
contemporaneous CDx currently in development, the decision to invest in a CDx 
program was made in the preclinical stages. Another 19% of the drugs got their CDx 
investment in phase I of their development. There were a handful of decisions made 
in phase II (6%) and minimal investment decisions made in phase III or post launch.      
Discussion 
Until recently, the CDx strategy for most drug developers was to wait until receiving 
FDA approval for their drug, and only then, if it made commercial sense, make that 
extra investment into developing a CDx. In few cases, a Phase III failure could also 
motivate the drug developer to investigate the possibility of investing into a CDx, to 
give their drug another shot at approval.  
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However, in the last 5 years the trend has been shifting towards exploring the 
possibility of co-developing a companion diagnostic right from the discovery stages, 
when core decisions about target selection and associated biomarkers are being 
made. This can be demonstrated by the data collected for this question – of all drugs 
being co-developed with CDx today, 91% of the programs were initiated in the 
preclinical and phase I of development.      
 
Translated which means, that most oncology firms today are embracing the idea 
of developing personalized therapies for a stratified population, which could 
lead to superior clinical outcomes and better therapy compliance25, which in turn 
could establish their drug’s comparative effectiveness26, thus allowing them to 
achieve premium pricing for their launches. Moreover, launching their drug as a first 
or best in class therapeutic, with a proprietary CDx could potentially raise the 
barrier to entry for future competitors – hence prolong their drug’s lifecycle. 
                                                        
25 Silver et al (2009), The Case for Personalized medicines, Ernst & Young Global Biotechnology Center, Personalized Medicine 
Coalition, page 3 
26 Weinstein MC, Skinner JA. Comparative effectiveness and health care spending—implications for reform. N Engl J Med 
2010;362:460–465. 
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Question 10: 
What are the chief considerations that may influence the investment decision for a 
CDx development program? 
Rationale 
Only a handful of oncology companies today have a fully integrated diagnostic 
division; the majority of CDx co-development depends on collaborations with 
external partners27, as evidenced by the rise of oncology biomarker and diagnostic 
deals in the past few years – from just 15 in 2006, to over 200 deals in 201128. 
Consequently, to appreciate the motivations of drug developers while inking these 
deals became crucial to testing my hypothesis.  
Results 
Among all motivations for developing a CDx, the drug developers ranked adoption of 
                                                        
27 Dawkes, A., (2007), The Strategic Importance of Biomarkers to the Pharmaceutical Industry, available at 
http://files.pharmaventures.com/biomarkers_pharmaventures.pdf, Accessed Aug 21, 2011 
28 Poile, S., (2011), Recent trends in personalized medicine oncology deal making, available at 
http://www.londonbiotechnology.co.uk/Events-and-publications/Publications/Recent-trends-in-personalized-medicine-
oncology-de.aspx, Accessed Aug 21, 2011   
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Figure 14: Chief Considerations - CDx Development Strategy 
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the CDx by the physicians and the assays’ effectiveness in making clear clinical 
decisions, as being most important.   
Discussion 
The feedback from the interviewees clearly indicated that the ability of a CDx in 
assisting physicians make treatment choices in the clinic was the prime 
motivator for developing it. It was less important for the drug developers to enter 
into a CDx co-development agreement merely to improve their ability to capture 
market share, which demarcates a clear departure from the earlier stand of 
biopharmaceutical companies (McKinsey, 2009) 29 to employ a CDx strategy only in 
the later stages to maximize the revenue potential of their therapeutic. 
 
Question 9: 
What is your preferred approach towards a CDx development program? Please 
briefly mention your rationale. 
Rationale 
The goal was to unearth if a particular CDx development approach was attractive to 
small and large oncology firms alike, and additionally understand that besides 
external partnerships, what other strategies were being employed by firms to 
enhance the co-development nexus between their drug and diagnostic. 
Results 
80% of drug developers favored external partnerships, and only a couple of large 
biopharmaceuticals chose internal development strategy as their first preference. 
                                                        
29 Ma et al. (2009) The microeconomics of personalized medicine: Today’s challenge and tomorrow’s promise, Nature Reviews 
Drug Discovery Vol. 8 April 2009, 279 - 286  
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Discussion 
Considering that only Roche and Novartis in the study group had an internal 
diagnostic division, their preference to develop CDx internally is well understood. 
For the rest of the study participants, external partnerships made most sense, 
especially considering the amount of resources needed to build a new non-core 
business with low margins. However, few of the large biopharmaceuticals also noted 
that with a more favorable regulatory and payer environment, they would consider 
internal development of their CDx or even prefer it.  
 
Question 12: 
Would you launch a 2nd or 3rd in class drug to market without a CDx, if the first 
therapy to market did not launch with one? Please explain briefly. 
Rationale 
The aim here was to understand the role of CDx in capturing market share in an 
undifferentiated market. 
Acquire a relevant BM or CDx company
In-license CDx technology
Out-license technology to Dx company
Use an existing Dx test
Develop internally
Partner externally (co-develop)
Figure 15: Ranking of CDx Development Strategies - Participant Firms 
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Results 
The question provoked interesting responses from the interviewees, few chosen 
ones are presented here: 
Large biopharmaceutical executives: 
- “It depends. Our aim is to differentiate our drug right from the launch and 
show superior value via better efficacy and safety data, so if a CDx helps our 
cause, we will invest for developing one” 
- “Yes, if the NPV is positive” 
- “If we could isolate a patient population that closely matched our drug’s 
profile based on science and data, and allowed us to corner a market – the 
non-CDx path is better, it’s less complex and saves resources” 
 Small biotechnology executives: 
- “Generally speaking we’ll shy away from ‘me-too’ approaches, unless we 
could show efficacy where others have failed – which may well require a CDx 
approach” 
- “Yes, there is a strong business case for launching more efficacious drugs in 
several crowded markets – a CDx is not always necessary to cross the bar” 
- “Yes, if the efficacy and benefit/risk profile of the drug in a defined niche 
population is superior to competitors”    
Discussions 
In the view of the interviewees, within oncology, it increasingly making less sense to 
launch a “me-too” drug – any new launch must significantly improve the efficacy 
and safety outcomes for patients compared to existing therapies. 
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5.5 Personalized Medicine – Challenges 
Question 14: 
In addition to what has been covered above – what else in your view encourages or 
discourages the inclusion of a CDx program during the course of drug development?  
Rationale 
With an open ended question like this, the objective here was to explore – what, if 
anything still hindered the oncology drug developers from increasing the 
proportion of companion diagnostic driven personalized medicine launches in years 
to come. 
Results 
This was one of the most profusely discussed portions of the interview and evoked 
passionate responses from the interviewees, few of which are accounted below: 
- “Co-development is not easy; the approaches differ significantly for the drug 
and diagnostic development, so bringing them together on the same page in 
quite challenging. Historically the industry has not been structured for this 
kind of work, although things are changing” 
- “Finding the right development partner is crucial – if the incentives are not 
aligned - it’s almost impossible to make progress” 
- “The fact that you need to file for a NDA and a PMA simultaneously in two 
different sections of the FDA doesn’t help” 
- “A single stable technology platform during development is critical, any loss 
of data can set you back by years, and standardization of hardware, software 
and test reagents through the life of a project still poses a major challenge” 
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Discussion 
Consolidating the findings from this section of the interview, gives an impression 
that the presence of a distinct biomarker, and its co-development as a CDx, at least 
in theory, has the potential to bestow on its associated drug in development, the 
benefits of an orphan drug – fast track approval, premium pricing and possibly a 
monopolistic market position, reasons that should adequately encourage drug 
developers to think about co-development of a CDx. However, the dearth of CDx 
associated launches, indicate towards developmental or launch hurdles – potentially 
due to the misaligned perspectives and incentives of the stakeholders involved30. 
Despite known benefits, there are several challenges to biomarker driven drug 
discovery and co-development of CDx within the current environment, which could 
discourage an oncology drug developer in taking on the personalized medicine 
approach to R&D. Some of these challenges are illustrated below: 
Scientific Challenges 
 Our ability to truly appreciate the complex molecular mechanisms of a 
heterogeneous disease like cancer is still limited, and by extension so is our 
understanding of the mechanism of action of drugs used for treating it 
 Target identification and validation is largely hypothesis driven, and less 
often data driven, which adds to the complexity of accurately isolating a clear 
biomarker early in the drug discovery process 
 Lack of relevant animal models to identify and develop candidates, make 
biomarker discovery inefficient and cumbersome 
                                                        
30 Dunn et al, Advocacy in personalized medicine: a developing strength in a complex space, Personalized Medicine (2010) 
7(2), 179-186 
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 Most conduct the work in humans, due to a lack of models but also due to the 
limited availability of diverse tissue types in tissue banks, which restrict the 
extent to which prospective studies can be conducted 
Economic Challenges 
 Until recently, the economic incentives for drug developers to co-develop a 
CDx has remained largely unclear 
 CDx by themselves are not widely reimbursed, hence its appeal as a 
standalone business model is limited 
Regulatory Challenges 
 Despite the proposed guidance on July 14th, 2011 (Appendix D), the obscurity 
of FDA policies for development and approval of CDx, keep co-development a 
daunting undertaking for majority of oncology drug developers 
Industry Legacy Challenges 
 Historically, the pharmaceutical industry has been organized for producing 
mass used products, therefore to many the concept of stratification of patient 
population still sounds like the death knell of a potential blockbuster. 
Consequently, even until 2009, several corporations confirmed that CDx was 
not a priority and they were taking a ‘cautious’ approach to investments31  
 The realization that the payer attitude towards reimbursement of 
oncology therapies is shifting from ‘pay to play’ to ‘pay to perform’, is 
gradual across the industry, leading to a continued wait-and-watch approach 
towards the success of CDx co-development programs 
                                                        
31 Ma et al. (2009) The microeconomics of personalized medicine: Today’s challenge and tomorrow’s promise, Nature Reviews 
Drug Discovery Vol. 8 April 2009, 279 - 286 
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Notwithstanding the challenges noted above, several interviewees observed that in 
the last 5 years the biopharmaceutical industry’s mindset has been shifting slowly, 
and since it takes time to develop drugs, it will be sometime before this shift can be 
witnessed in CDx associated drug launches.  
 
Given that perspective, and also considering that today the biopharmaceutical 
industry has a lot more targeted therapeutics in the pipeline than ever before and 
some of them, like Zelboraf and Xalkori, are on the market, most interviewees 
concurred that it is safe to assume that the value proposition of co-developing a CDx 
is beginning to be appreciated across the industry, and that this strategic approach 
to drug development has probably achieved critical mass.  
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6. Conclusion 
The aim of the study was to test my hypothesis that in the next 5 years, CDx 
associated drug launches could exceed the current trend by at least 100% i.e. could 
double, and also to ascertain if increasing prices and market share of launched drugs 
were the top drivers for CDx investments.  
 
Based on data collected from the interviews, whereas only 15% of the drugs 
marketed by the participants firms have a CDx, their current oncology pipelines has 
on average 54% drugs associated with a predictive biomarker across all phases of 
development, of which 62% are being developed as a companion diagnostic. Thus, 
across all oncology drugs in development, within the firms represented, close to 
34% of drugs have a CDx in development (Figure 6), which means that in this 
decade a much larger proportion of oncology drugs would be launched with a CDx. 
More specifically, the participants expect their firms to launch close to 34 oncology 
drugs in the next 5 years, of which 20 are expected to be launched with a 
contemporaneously developed CDx (Figure 8). Considering that in the previous 
three 5-year periods the share of CDx associated oncology drug launches has been 
12%, 20% and 17% (Figure 8) – the expectation that the share in the next 5 years 
would be 59%, indicates a jump of more than 350% - which refutes my hypothesis.  
 
Further, the data indicated that of all expected oncology launches from the 
participating firms, nearly 90% were expected to be launched either as 1st or 2nd in 
class (Figure 9), which are launch positions where conventionally drugs do not need 
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to focus on capturing market share from an existing competitor, which suggests that 
investments in predictive biomarkers were not being driven by pricing or market 
share concerns. Additional data confirmed that the investment for discovering 92% 
of the predictive biomarkers were made either in preclinical or phase I stages of 
drug development (Figure 11) - similar results were observed for CDx investment 
decisions as well (Figure 13), these findings support the assertion that the 
developers’ decision to invest in predictive biomarkers and develop them as CDx, 
were NOT driven by an objective to increase prices or market share of their 
associated drugs’ post launch. Furthermore, results obtained from the drug 
developers ranking of reasons for investing in discovering a predictive biomarker 
(Figure 12) and developing a CDx (Figure 14) confirmed that shortening the drug 
development time and improving the quality of decisions during development was 
more important, than raising prices and enhancing market share – both of which 
were ranked lower than the top 5 reasons. Taken together, these observations 
falsify my hypothesis that increasing prices and market share of launched drugs are 
the top drivers for making predictive biomarker discovery and CDx development 
investments. 
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6.1 Limitations 
Bearing in mind that today there are in excess of 2,500 oncology drugs in various 
stages of development32, this study just scratches the surface in terms of isolating 
drugs in development that may be utilizing a biomarker strategy or co-developing a 
CDx – but then, the study was never designed to reach statistically significant 
conclusions.  
The selection of companies and participants was driven by a conscious effort to 
learn from the perspectives of a broad genre of oncology drug developers, in various 
stages of maturity. Nonetheless, the possibility that a selection bias might have crept 
in and partially skewed the study’s outcome - is real, some of which are presented 
below: 
Participant Selection Bias  
Although 90% of all participants selected for the study responded, the selection was 
based on personal contacts and networks, where few of the interviewees knew each 
other, which may have induced some degree of collective bias in their perspective. 
Company Selection Bias  
While the inclusion of 4 top oncology companies33, with a market share in excess of 
60%, ensured that the study had a solid foundation, the perspectives gathered from 
some of the most promising oncology startups guaranteed that the study benefitted 
from the cutting edge thinking around early stages of oncology drug development. 
However, addition of few midsize firms could have furthered enhanced the study’s 
integrity. 
                                                        
32 Pharma R&D Annual Review 2010, Pharma Projects, available at: 
http://www.pharmaprojects.com/therapy_analysis/annual-review-2010-therapies.htm Accessed at Aug 28, 2011 
33 IMS Health MIDAS MAT December 2010  
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Geography Selection Bias  
Considering that most interviews were conducted with firms based in US or EU, and 
none from emerging markets, the study’s results cannot be extrapolated globally. 
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7. Discussion 
Although, the concept of personalized medicine pervades several therapy areas, it is 
more frequently explored within oncology, and considering that majority of the CDx 
associated drug launches have been within oncology – it was chosen to be the focus 
of this study.  
 
Designed as a pilot study to examine the prevailing trends in oncology drug 
development, in particular pertaining to the use of biomarkers in drug discovery 
and co-development of companion diagnostics, the aim was to get an impression of 
the extent of expected CDx associated drug launches in the next 5 years, and to 
develop an understanding of the oncology drug developers’ motivations when 
embarking on a CDx co-development program.  
 
Drawing on the interviewees’ responses, it was apparent that the core business 
question for oncology firms, like any other business, remains unchanged – how to 
secure a market quickly and efficiently, and how to keep it secure for the 
longest possible duration. In other words, the more closely aligned the market 
definition is to the drug’s profile, the harder it is for the competition to break in. 
Isolating a clear biomarker during discovery and co-developing it as a CDx are yet 
another set of tools that can be used to identify a market, and emphatically win the 
battle of efficacy and safety between oncology brands within a defined market.  
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While there is consensus that biomarker driven discovery and development 
improves the probability of success of a drug program, the wisdom of co-developing 
the biomarker as a CDx is still questioned – drug developers do not want to target 
smaller populations. However in the wake of recent successes of CDx associated 
drug launches like Zelboraf and Xalkori, it is becoming clearer that the benefits of 
co-developing a CDx outweigh the risks and costs.  
 
That a BM narrows the patient population is true, but that gives the potential for 
greater efficacy in selected patients, as the underlying mechanism is better defined. 
Considering that clinical trials are the single-largest expense item associated with 
drug development, both in terms of cost of recruitment and the time taken to recruit 
the relevant patients – it pays to have a selected population, which is more likely to 
respond well. Smarter, shorter clinical trials not just increase the probability of a 
drug’s success but allow for a premium pricing option for the drug on approval. 
Taken together, the higher probability of success, lower development costs, 
shorter time to market, pricing power and potential to corner a market or 
secure an increased market share – are serious economic benefits, which can 
more than offset the risks and cost of co-developing a CDx.  
 
Essentially, the study refutes the initial hypothesis, and instead indicates that in the 
next 5-10 years the number and proportion of CDx associated drug launches would 
significantly increase, which is evidenced by the trends observed in the current 
pipeline of participating oncology companies.  
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Moreover, recent data obtained from Roche – the largest oncology company in the 
world, point towards the rise in collaborations between Roche’s biopharmaceutical 
and diagnostic arms, from just 1 CDx project in 2006, to 22 in 2010 – of which most 
were in oncology34 - further endorses the study’s finding that CDx associated drug 
launches in oncology would become more common within this decade.  
 
Additionally, an analysis of drug developers’ motivations for adopting a biomarker 
driven CDx co-development strategy, failed to confirm the hypothesis that 
increasing price and market share of launched drugs was more important to drug 
developers, on the contrary most drug developers wanted to use biomarkers to 
increase their drug’s probability to launch, by making more informed go/no-go 
decisions along the developmental pathway and, to reduce the time it takes to 
launch their drug.  
 
Bottom line, in oncology, launching more efficacious drugs, more efficiently, will be 
the key to future commercial success – it no longer matters if the launch is a 
blockbuster or a nichebuster.  
 
  
                                                        
34 Roche Presentation - ASCO 2011, 47th Annual ASCO Meeting, Roche Analyst Event, Sunday June 5, 2011 - Chicago 
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7.1 Further Research 
It was in the midst of this study, on July 14th that FDA proposed guidelines for the 
development and approval of CDx. Although the proposed development pathway is 
still complicated, the policies do bring clarity to the processes involved, and is likely 
to encourage drug developers interested in pursuing a co-development strategy. 
More importantly though, with two fast approvals of Zelboraf and Xalkori, all within 
the timeframe of writing this thesis, FDA has in-effect reinstated its stance 
(Appendix D) on CDx associated drug launches, which in effect will encourage more 
drug developers to consider this strategy.  
 
In light of these events, this study should serve as a roadmap for follow-up research 
with larger, more balanced samples of drug developers, to gain a broader 
perspective on co-development of CDx as a strategic approach, for launching safer, 
more efficacious and premium priced oncology drugs, within record approval times.  
 
Future studies should also include other key stakeholders, such as providers and 
payers, so that their impact on the strategic choices made by oncology drug 
developers can also be appreciated.  
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7.2 Implications  
Oncology companies today, have to continue being opportunistic and data driven 
while making strategic development decisions – a dogmatic approach to 
biomarkers, or making a companion diagnostic strategy mandatory for every drug 
candidate is not conducive to the high risk, and fast evolving environment of cancer 
drug development.  
 
That being said, the transition of companion diagnostics from a ‘nice to have’ to 
a ‘must have’ is inevitable - as crowding in oncology therapies become rampant 
with more drugs targeting the same pathway and molecular target.  
 
In essence, contemporaneously developed companion diagnostics are a potent 
strategy for truly differentiating novel oncology therapeutics and showing superior 
value to stakeholders involved. 
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Appendix A: List of Oncology Therapeutics approvals1 (1995 – 2011) 
 
 
Oncology Drugs with a companion diagnostic on the market2 
                                                          
1 CenterWatch, FDA Approved Drug Therapies in Oncology, available at: http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx?AreaID=12 Accessed Aug 13, 2011  
2 Cohen, J., Tufts CSDD Report, Volume 13, Number 4, Page 2, July/August 2011 
Cancer NDA Approvals - USA FDA -1995 - 2011 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Ethyol Aredia Femara Herceptin Aromasin Mylotarg Gleevec Eloxatin Iressa Alimta Arranon Dacogen Ixempra Treanda Afinitor Halaven Sylatron 
Intron A Arimidex Gliadel Neupogen Busulfex Trisenox Zometa Faslodex Velcade Clolar Nexavar Sprycel Tasigna Mozobil Folotyn Jevtana Caprelsa 
Leukine Camptosar Rituxan Nolvadex Doxil Trelstar Femara Eligard Plenaxis Tarceva Revlimid Sutent Torisel Degarelix Istodax Provenge Yervoy 
 
Eulexin Taxol Photofrin Ellence Viadur Campath Neulasta UroXatral Vidaza 
 
Zolinza Tykerb 
 
Votrient Xgeva Zytiga 
 
Gemzar 
 
Proleukin Temodar PACIS 
 
Zevalin Bexxar Sensipar 
 
Vectibix Hycamtin 
 
Arzerra 
 
Zelboraf 
 
Hycamtin 
 
Valstar 
     
Avastin 
      
Adcetris 
 
Lupron 
 
Xeloda 
     
Erbitux 
      
Xalkori 
 
Taxotere 
               
 
Zoladex 
               
3 9 4 7 5 5 4 5 5 7 3 5 5 3 5 4 7 
0 1 0 1 0 1 1 0 1 2 0 2 2 0 0 0 2 
Drugs with Companion Diagnostic 
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 Industry	  Survey	  for	  Student	  Research 	  
Name	   	  Position	   	  Company	   	  Phone	   	  	  
Despite	   the	   widely	   accepted	   promise	   of	   biomarker	   (BM)	   and	   companion	  
diagnostics	   (CDx)	   in	   improving	   outcomes	   for	   cancer	   patients,	   payors	   and	  
regulators	  –	   there	  are	  but	  a	   few	  examples	  of	  successful	  prospective	  diagnostic	  
and	  therapeutic	  co-­‐development.	  Why??	  	  Please	  answer	  the	  following	  questions	  based	  on	  your	  own	  experiences,	  perceptions,	  and	  opinions.	  Your	  responses	  will	  be	  kept	  strictly	  confidential	  and	  anonymous,	  and	  will	  be	  used	  solely	  in	  connection	  with	  my	  research	  as	  a	  graduate	  student	  in	  the	  Biomedical	  Enterprise	  Program	  of	  the	  Harvard-­‐MIT	  Division	  of	  Health	  Sciences	  and	  Technology	  and	  MIT	  Sloan	  School	  of	  Management.	  	  Question	  1:	  How	  long	  have	  you	  been	  associated	  with	  commercialization	  of	  oncology	  products,	  and	  in	  what	  roles?	  	  
Experience	  (Tick	  one)	   Roles	  (Please	  mention	  all	  that	  apply)	  5-­‐10	  years	   	   1.	   	  10-­‐15	  years	   	   2.	   	  15-­‐20	  years	   	   3.	   	  >	  20	  years	   	   4.	   	  	  Question	  2:	  How	  many	  oncology	  drug	  development	  projects	  and	  launches	  have	  you	  been	  involved	  with?	  Of	  those,	  how	  many	  had	  an	  associated	  BM	  during	  drug	  development	  and	  how	  many	  were	  actually	  launched	  with	  a	  CDx?	  	  
#	  Projects	   #	  Launches	   #	  Associated	  BM	   #	  Launched	  with	  a	  CDx	  	   	   	   	  	  Question	  3:	  What	  is	  your	  company’s	  approximate	  annual	  revenue	  from	  oncology	  products?	  	  Also,	  what’s	  your	  approximate	  annual	  R&D	  budget	  within	  oncology?	  	   <	  $100	  M	   $100	  –	  $500M	   $500M	  –	  $1B	   >	  $1	  B	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Annual	  R&D	  budget	  –	  Oncology	  	   $	  	  	  Question	  4:	  Please	  complete	  the	  following	  about	  your	  current	  oncology	  pipeline	  products:	  a. The	  number	  of	  drugs	  currently	  in	  development,	  across	  various	  phases?	  b. Of	  those,	  the	  number	  of	  drugs	  that	  have	  an	  associated	  BM?	  c. Of	  those,	  the	  number	  those	  currently	  have	  a	  CDx	  co-­‐development	  program?	  	  
Drug	  stage	   #	  Drugs	  in	  pipeline	   #	  Associated	  BM	   #	  Associated	  CDx	  Preclinical	   	   	   	  Phase	  I	   	   	   	  Phase	  II	   	   	   	  Phase	  III	   	   	   	  Marketed	   	   	   	  	  Question	  5:	  Of	  the	  drugs	  in	  your	  pipeline	  with	  an	  associated	  BM,	  at	  what	  stage	  of	  their	  drug	  development	  was	  the	  decision	  to	  invest	  in	  their	  BM	  development	  implemented?	  	  
#	  Preclinical	   #	  Phase	  I	   #	  Phase	  II-­‐a	   #	  Phase	  II-­‐b	   #	  Phase	  III	   	  #	  Marketed	  	   	   	   	   	   	  	  	  	  	  	  Question	  6:	  What	  drove	  the	  investment	  timing	  in	  these	  BM	  development	  decisions?	  Please	  rank	  the	  following	  reasons	  in	  their	  order	  of	  importance	  (1	  =	  most	  &	  11	  =	  least).	  If	  your	  rationale	  differed	  across	  your	  pipeline,	  please	  rank	  for	  your	  top	  3	  candidates.	  	  
Reasons	  for	  Investment	   Drug	  1	   Drug	  2	   Drug	  3	  Decrease	  trial	  size	   	   	   	  Reduce	  patient	  attrition	   	   	   	  Enhance	  market	  share	   	   	   	  Increase	  speed	  to	  market	   	   	   	  Support	  higher	  drug	  prices	   	   	   	  Improve	  Go	  /	  No-­‐Go	  decisions	   	   	   	  Establish	  cost	  vs.	  benefit	  upfront	  	   	   	   	  Establish	  comparative	  effectiveness	   	   	   	  Explore	  label	  expansion	  of	  the	  therapy	   	   	   	  Clinical	  need	  for	  a	  companion	  diagnostic	   	   	   	  Reducing	  side-­‐effect	  profile	  of	  the	  drug	  	   	   	   	  	  Question	  7:	  Of	  the	  drugs	  in	  your	  pipeline	  with	  an	  associated	  BM,	  in	  your	  view,	  how	  many:	  -­‐ Are	  likely	  to	  be	  launched	  in	  the	  next	  5	  years?	  -­‐ What	  would	  be	  the	  expected	  position-­‐in-­‐class	  at	  launch?	  -­‐ Also,	  of	  those	  how	  many	  would	  be	  launched	  with	  an	  associated	  CDx?	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#	  Drug	  Launches	   1st	  in	  class	   2nd	  to	  launch	   2	  –	  4	  in	  market	   >4	  competitors	  	   	   	   	   	  
With	  a	  CDx	   	   	   	   	  	  Question	  8:	  Of	  the	  drugs	  in	  your	  pipeline	  that	  have	  an	  established	  associated	  CDx	  program,	  at	  what	  stage	  of	  their	  BM	  development	  was	  the	  decision	  to	  invest	  in	  a	  CDx	  made?	  	  
#	  Preclinical	   #	  Phase	  I	   #	  Phase	  II-­‐a	   #	  Phase	  II-­‐b	   #	  Phase	  III	   	  #	  Marketed	  	   	   	   	   	   	  	  Question	  9:	  What	  is	  your	  preferred	  approach	  towards	  a	  CDx	  development	  program?	  Please	  select	  one,	  or	  more	  if	  multiple	  approaches	  are	  being	  employed.	  	   Develop	  internally	   	  Use	  an	  existing	  Dx	  test	   	  In-­‐license	  CDx	  technology	   	  Partner	  externally	  (co-­‐develop)	   	  Out-­‐license	  technology	  to	  Dx	  company	   	  Acquire	  a	  relevant	  BM	  or	  CDx	  company	   	  	  Why?	  Please	  briefly	  mention	  your	  rationale.	  	  Question	  10:	  What	  are	  the	  chief	  considerations	  that	  may	  influence	  the	  investment	  decision	  for	  a	  
CDx	  development	  program?	  Please	  rank	  the	  following	  in	  their	  order	  of	  importance	  (1	  =	  most	  &	  10	  =	  least).	  	  	  If	  the	  investment	  rationale	  differs	  for	  each	  CDx,	  please	  rank	  the	  considerations	  below	  for	  the	  top	  3	  CDx	  development	  programs	  that	  you	  were	  involved	  with.	  	  
Consideration	  for	  a	  CDx	   CDx	  1	   CDx	  2	   CDx	  3	  Would	  it	  be	  approved?	   	   	   	  Would	  physicians	  use	  it?	   	   	   	  Would	  it	  be	  reimbursed?	   	   	   	  Is	  there	  a	  large	  clinical	  need?	   	   	   	  Would	  be	  it	  clinically	  effective?	   	   	   	  Would	  it	  reduce	  adverse	  events?	   	   	   	  Would	  it	  help	  capture	  mkt.	  share?	   	   	   	  Would	  it	  save	  costs	  for	  the	  payors?	   	   	   	  Would	  it	  reduce	  the	  target	  market?	   	   	   	  Could	  it	  become	  the	  gold	  standard?	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Question	  11:	  Would	  you	  take	  a	  candidate	  forward,	  in	  absence	  of	  an	  associated	  biomarker,	  and	  under	  what	  circumstances?	  Please	  explain	  briefly.	  	   	  	  	  	  Question	  12:	  Would	  you	  launch	  a	  2nd	  or	  3rd	  –	  in	  –	  class	  drug	  to	  market	  without	  a	  CDx,	  if	  the	  first	  therapy	  to	  market	  did	  not	  launch	  with	  one?	  Please	  explain	  briefly.	  	   	  	  
	  Question	  13:	  What	  in	  your	  view	  is	  the	  approximate	  cost	  of	  bringing	  an	  oncology	  drug	  to	  market?	  Of	  that,	  what	  percentage	  is	  the	  additional	  cost	  of	  co-­‐developing	  a	  BM?	  In	  essence,	  what	  is	  the	  total	  cost	  of	  bringing	  an	  oncology	  drug	  with	  a	  CDx	  to	  market?	  	  
Launch	  Strategy	   Cost	  of	  Development	  ($)	  Drug	  Only	   	  Drug	  +	  Proven	  Biomarker;	  but	  no	  CDx	   	  Drug	  +	  Effective	  Companion	  Diagnostic	   	  	  Question	  14:	  In	  addition	  to	  what	  has	  been	  covered	  above	  –	  what	  else	  in	  your	  view	  encourages	  or	  discourages	  the	  inclusion	  of	  a	  CDx	  program	  during	  the	  course	  of	  drug	  development?	  	  	   	  
	  Thank	  you	  indeed	  for	  your	  thoughts	  and	  time!!	  I	  will	  send	  you	  a	  copy	  of	  my	  thesis	  with	  the	  consolidated	  output	  from	  this	  industry	  wide	  survey	  later	  this	  fall.	  	  Best	  regards,	  	  Anand	  Mehrotra,	  BPharm'94,	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Draft Guidance for Industry and 
Food and Drug Administration Staff 
  
 
In Vitro Companion Diagnostic 
Devices  
  
 
This draft guidance, when finalized, will represent the Food and Drug Administration's 
(FDA's) current thinking on this topic.  It does not create or confer any rights for or on any 
person and does not operate to bind FDA or the public.  You can use an alternative approach 
if the approach satisfies the requirements of the applicable statutes and regulations.  If you 
want to discuss an alternative approach, contact the FDA staff responsible for implementing 
this guidance.  If you cannot identify the appropriate FDA staff, call the appropriate number 
listed on the title page of this guidance.  
  
 
I. Introduction  
 
This guidance is intended to assist (1) sponsors who are planning to develop a therapeutic 
product1 that depends on the use of an in vitro companion diagnostic device (or test) for its safe 
and effective use and (2) sponsors planning to develop an in vitro companion diagnostic device 
that is intended to be used with a corresponding therapeutic product.     
 
Specifically, the guidance intends to accomplish the following:  
 
x Define in vitro companion diagnostic device (hereafter referred to as an “IVD companion 
diagnostic device”) 
x Explain the need for FDA oversight of IVD companion diagnostic devices 
x Clarify that, in most circumstances, if use of an IVD companion diagnostic device is 
essential for the safe and effective use of a therapeutic product, the IVD companion 
diagnostic device and therapeutic product should be approved or cleared 
contemporaneously by FDA for the use indicated in the therapeutic product labeling 
x Provide guidance for industry and FDA staff on possible premarket regulatory pathways 
and FDA’s regulatory enforcement policy 
                                                          
1 As used in this guidance, therapeutic product includes therapeutic, preventive, and prophylactic drugs and 
biological products.  Although this guidance does not expressly address therapeutic devices intended for use with in 
vitro diagnostics, the principles discussed in this guidance may also be relevant to premarket review of such devices. 
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x Describe certain statutory and regulatory approval requirements relevant to therapeutic 
product labeling that stipulates concomitant use of an IVD companion diagnostic device 
to ensure safety and effectiveness of the therapeutic product   
FDA encourages sponsors considering developing either the therapeutic or IVD companion 
diagnostic devices discussed in this guidance to request a meeting with both relevant device and 
therapeutic product review divisions to ensure that product development plans will produce 
sufficient data to establish the safety and effectiveness of the IVD companion diagnostic 
device/therapeutic product pair. 
 
FDA's guidance documents, including this guidance, do not establish legally enforceable 
responsibilities.  Instead, guidances describe the Agency's current thinking on a topic and should 
be viewed only as recommendations, unless specific regulatory or statutory requirements are 
cited.  The use of the word “should” in Agency guidances means that something is suggested or 
recommended, but not required.  
 
 
II. Background 
 
Diagnostic tests have been employed for many years to enhance the use of therapeutic products. 
Tests are also used during therapeutic product development to obtain the data FDA uses to make 
regulatory determinations.  After a therapeutic product is commercially available for use, health 
care professionals may use a relevant diagnostic test, for example, to select the appropriate 
patient for a particular therapy or to optimize a dosing regimen.   
 
Recently, the development of therapeutic products that depend on the use of a diagnostic test to 
meet their labeled safety and effectiveness claims has become more common.  For example, such 
a test can identify appropriate subpopulations for treatment or identify populations who should 
not receive a particular treatment because of an increased risk of a serious side effect.  One 
reason for increasing interest is the emergence of new technologies that can distinguish subsets 
of populations that respond differently to treatment. These technologies are making it 
increasingly possible to individualize, or personalize, medical therapy by identifying patients 
who are most likely to respond, or who are at lower or higher risk for a particular side effect.   
 
When an appropriate scientific rationale supports such an approach, FDA encourages the 
development of therapeutic products that depend on the use of approved or cleared IVD 
companion diagnostic devices — several such IVD companion diagnostic devices for use with 
corresponding therapeutic products have already been approved or cleared.2 
 
When results from a diagnostic device are a determining factor in patient treatment, health care 
professionals must be able to rely on those results. Inadequate performance of an IVD 
companion diagnostic device could have severe therapeutic consequences.  Such a device might 
2 Examples of currently approved IVD companion diagnostic devices that illustrate the importance of established 
performance parameters for both the therapeutic product and the IVD companion diagnostic device include FDA 
approved HER-2 testing to determine whether Herceptin (trastuzumab) therapy is indicated for treatment of 
metastatic breast cancer and gastric cancer.  Herceptin lacks effectiveness in the HER-2 marker negative population, 
and also has the possibility of causing severe adverse effects.  Therefore it is important to use an IVD companion 
diagnostic device to identify only those patients who could benefit from the therapy.  
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fail analytically (e.g., by not accurately measuring the expression level of a protein of interest), 
or clinically (e.g., by not identifying those patients at increased risk for a serious adverse effect).  
Erroneous IVD companion diagnostic device results could lead to withholding appropriate 
therapy or to administering inappropriate therapy.  Therefore, FDA believes that use of an IVD 
companion diagnostic device with a therapeutic product raises important concerns about the 
safety and effectiveness of both the IVD companion diagnostic device and the therapeutic 
product.  Because an IVD companion diagnostic device with inadequate “performance 
characteristics”3 or other issues related to safety and effectiveness could expose a patient to 
preventable treatment risks, FDA will assess the safety and effectiveness of the IVD companion 
diagnostic device as used with the therapeutic when a therapeutic product depends on the IVD 
companion diagnostic device for its safe and effective use.   
 
To facilitate the development and approval of therapeutic products that are intended for use with 
IVD companion diagnostic devices, as well as the development of the IVD companion diagnostic 
devices themselves, FDA is clarifying relevant policies related to these devices and products.  
FDA is also developing appropriate internal policies and procedures to ensure effective 
communication among the relevant centers and to promote consistent and efficient product 
review.4  
 
 
III. Definition and Use of an IVD Companion Diagnostic 
Device 
 
An IVD companion diagnostic device is an in vitro diagnostic device that provides information 
that is essential for the safe and effective use of a corresponding therapeutic product.5  The use 
of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the 
instructions for use in the labeling of both the diagnostic device and the corresponding 
therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic 
product.  
 
 An IVD companion diagnostic device could be essential for the safe and effective use of a 
corresponding therapeutic product to:  
 
x Identify patients who are most likely to benefit from a particular therapeutic product6  
3 See 21 CFR 809.10 (b)(12). 
4 In some cases, an IVD companion diagnostic device intended for use with a therapeutic product and that 
therapeutic product may together constitute a “combination product.”  See 21 CFR 3.2(e)(3) and (4).  Whether an 
IVD companion diagnostic device and therapeutic product would together, in fact, constitute a combination product 
should be determined on a case-by-case basis.  Also, combination product status could affect regulatory 
requirements beyond the scope of this guidance.  For additional information, please contact the Office of 
Combination Products or refer to their webpage on the Agency’s website at 
http://www.fda.gov/CombinationProducts/default.htm 
5 Generally, this means that the use of the IVD companion diagnostic device with the therapeutic product allows the 
therapeutic product’s benefits to exceed its risks. 
6 This may include identifying patients in a specific population for which the therapeutic is indicated because there 
is insufficient information about the safety and effectiveness of the therapeutic product in any other population.  An 
example is a therapeutic that is indicated only for patients who by virtue of the presence of a marker in tumor cells 
are believed to be unlikely to respond to other therapies. 
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x Identify patients likely to be at increased risk for serious adverse reactions as a result of 
treatment with a particular therapeutic product  
x Monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, 
dose, discontinuation) to achieve improved safety or effectiveness  
 
FDA does not include in this definition clinical laboratory tests intended to provide information 
that is useful to the physician regarding the use of a therapeutic product, but that are not a 
determining factor in the safe and effective use of the product. 7   
  
Ideally, a therapeutic product and its corresponding IVD companion diagnostic device would be 
developed contemporaneously, with the clinical performance and clinical significance of the IVD 
companion diagnostic device established using data from the clinical development program of 
the corresponding therapeutic product — although FDA recognizes there may be cases when 
contemporaneous development may not be possible.  An IVD companion diagnostic device that 
supports the safe and effective use of a particular therapeutic may be a novel IVD device (i.e., a 
new test for a new analyte), a new version of an existing device developed by a different 
manufacturer, or an existing device that has already been approved or cleared for another 
purpose. 
  
The following section outlines FDA’s policy regarding approval of a therapeutic product for use 
with a corresponding IVD companion diagnostic device. 
 
 
IV. Review and Approval of IVD Companion Diagnostic 
Devices and Therapeutic Products 
 
Applications for an IVD companion diagnostic device and its corresponding therapeutic product 
will be reviewed and approved according to applicable regulatory requirements.  The IVD 
companion diagnostic device application will be reviewed and approved or cleared under the 
device authorities of the Federal Food, Drug, and Cosmetic Act (Act) and relevant medical 
device regulations; the therapeutic product application will be reviewed and approved under 
section 505 of the Act (i.e., drug products) or section 351 of the Public Health Service Act (i.e., 
biological products) and relevant drug and biological product regulations.8  FDA intends to 
review each IVD companion diagnostic device submission within the context of, or in 
 
 
7 Examples of such tests are commonly used and well understood biochemical assays (e.g., serum creatinine or 
transaminases) used to monitor organ function.  Note, however, that circumstances may occur when use of such 
tests, in the context of the therapeutic product, rises to an IVD companion diagnostic device level and approval or 
clearance for such use will be necessary.  Note also that a novel IVD device providing information that is useful in, 
but not a determining factor for the safe and effective use of a therapeutic product, would not be considered an IVD 
companion diagnostic device. 
8 To the extent an IVD companion diagnostic device and a therapeutic product together meet the definition of a 
combination product, a single application for the combination product may be submitted in some cases, though 
where appropriate, and the Agency may require separate applications for the constituent parts of the combination 
product.  See 21 CFR 3.4(c). 
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conjunction with, its corresponding therapeutic product, and FDA review of the test/therapeutic 
product pair will be carried out collaboratively among relevant FDA offices.   
 
A. Novel Therapeutic Products 
 
For a novel therapeutic product, an IVD companion diagnostic device should be developed and 
approved or cleared contemporaneously to support the therapeutic product's safe and effective 
use (e.g., co-development).  The results of the IVD companion diagnostic device will be 
essential for the safe and effective use of the therapeutic product, and its use will be stipulated in 
the labeling of the therapeutic product (i.e., the therapeutic product is considered safe and 
effective only if used with the IVD companion diagnostic device).  Before approving the 
therapeutic product, FDA will determine that the IVD companion diagnostic device is properly 
validated and meets the applicable standard for safety and effectiveness or for substantial 
equivalence for the use indicated in the therapeutic product’s labeling.  Because the IVD 
companion diagnostic device is essential to the safe and effective use of the therapeutic, with 
some exceptions (see next section), FDA does not believe it may approve a novel therapeutic 
product or new therapeutic product indication for use with an IVD companion diagnostic device 
if the IVD companion diagnostic device is not approved or cleared for that indication. Approval 
or clearance of the IVD companion diagnostic device will ensure that the device has been 
adequately evaluated and has adequate performance characteristics in the intended population.   
 
B. Approval of a Therapeutic Product without an Approved IVD Companion 
Diagnostic Device 
 
FDA may decide that it is appropriate to approve a therapeutic product even though the IVD 
companion diagnostic device for which it is labeled for use is not being approved or cleared 
contemporaneously.  Two such scenarios are discussed below.  In general, if a therapeutic 
product is approved without approval or clearance of its IVD companion diagnostic device, FDA 
expects that an IVD companion diagnostic device that is intended for use with the therapeutic 
will be subsequently approved or cleared through an appropriate IVD device submission, and the 
therapeutic product label will be revised to include the IVD companion diagnostic device.  In 
addition, FDA will consider whether additional protections are necessary to address the safety 
issues presented by the use of the therapeutic product without an approved or cleared IVD 
companion diagnostic device.9  
 
1.  New Therapeutic Products to Treat Serious or Life-Threatening Conditions 
 
FDA may decide to approve a therapeutic product even if its IVD companion diagnostic 
device is not yet approved or cleared when the therapeutic product is intended to treat a 
serious or life-threatening condition for which no satisfactory alternative treatment exists 
and the benefits from the use of the therapeutic product with an unapproved or uncleared 
IVD companion diagnostic device are so pronounced as to outweigh the risks from the 
lack of an approved or cleared IVD companion diagnostic device. 
 
9 Safety measures might include a risk evaluation and mitigation strategy (REMS), or a postmarket requirement, if 
necessary, 
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2. Already Approved Therapeutic Products 
 
FDA will generally not approve a supplement to an approved therapeutic product 
application to update the product’s labeling to stipulate the use of an IVD companion 
diagnostic device until the IVD companion diagnostic device is approved or cleared. 
Nevertheless, FDA recognizes that there may be occasions when the labeling for an 
already approved therapeutic product must be revised to address a serious safety issue 
and that the change made to address this issue may stipulate use of a diagnostic test that 
is not yet approved or cleared.  Under these circumstances, if the benefits from the use of 
the therapeutic product with an unapproved or uncleared IVD companion diagnostic 
device are so pronounced as to outweigh the risks from the lack of an approved or cleared 
IVD companion diagnostic device, FDA does not intend to delay approval of changes to 
the labeling of the therapeutic product until the IVD companion diagnostic device is 
approved or cleared.  
 
C. General Policies 
 
If safe and effective use of a therapeutic product depends on the use of an IVD companion 
diagnostic device, an approved or cleared IVD companion diagnostic device should be available 
for use once the therapeutic product is approved.  FDA expects that the therapeutic sponsor will 
address the need for an approved or cleared IVD companion diagnostic device in its therapeutic 
product development plan.  The sponsor of the therapeutic product can decide to develop its own 
IVD companion diagnostic device; the sponsor can partner with a diagnostic device sponsor to 
develop the appropriate IVD companion diagnostic device; or the sponsor can explore 
modification of an existing IVD diagnostic device(its own or another sponsor’s) to accommodate 
the appropriate intended use.  The following general policies apply whether a therapeutic product 
and its IVD companion diagnostic device are developed and manufactured by the same, or 
different, entities. 
 
x FDA will apply a risk-based approach to determine the regulatory pathway for IVD 
companion diagnostic devices, as it does with all medical devices.  This means that the 
regulatory pathway will depend on the level of risk to patients, based on the intended use 
of the IVD companion diagnostic device and the controls necessary to provide a 
reasonable assurance of safety and effectiveness. Thus, the level of risk together with 
available controls to mitigate risk will establish whether an IVD companion diagnostic 
device requires a premarket application (PMA) or, a 510(k),10  FDA advises sponsors to 
consult early with FDA on the likely regulatory pathway for the IVD companion 
diagnostic device.  Premarket review by FDA will determine whether the IVD 
companion diagnostic device has adequate performance characteristics for its intended 
use.   
x Except for the situations described in B, above, after completing review of the 
applications for a therapeutic product and an IVD companion diagnostic device and after 
determining that both products are ready for approval or clearance, FDA intends to issue 
approvals or approval and clearance for both products at the same time.  FDA strongly 
10 Experience indicates that most IVD companion diagnostic devices will be Class III devices, although there may 
be cases when a class II classification with premarket notification (510(k)) or other type of submission is 
appropriate. 
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encourages sponsors to time their clinical developments and premarket submissions to 
facilitate concurrent approval.  
x If an IVD diagnostic device is already legally marketed and the IVD diagnostic device 
manufacturer intends to market its device for a new use as an IVD companion diagnostic 
device for a novel therapeutic product, FDA would consider the new use of the IVD 
diagnostic device with the novel therapeutic product a major change in the intended use 
of the device, raising new or additional questions of safety and effectiveness (see 21 CFR 
807.81(a)(3)(ii), 814.39(a)).  Accordingly, an appropriate premarket submission (either 
PMA or 510(k)) for the new use must be approved or cleared for use with the novel 
therapeutic product.  
x New IVD companion diagnostic devices intended to be used in the same manner as an 
existing approved or cleared IVD companion diagnostic device (e.g., different 
manufacturer, different technological characteristics) will be reviewed under a PMA or a 
traditional 510(k), as appropriate. 
 
V. Labeling 
A. Therapeutic Product Labeling 
 
The Federal Food, Drug, and Cosmetic Act requires the labeling of prescription therapeutic and 
device products to include the information health care professionals need to use the products (21 
U.S.C. 352(f), 21 CFR 201.100(c)(1), Part 801.109(c), (d)). The labeling often includes 
information about diagnostic tests that determine how, when, or whether a therapeutic product is 
used.  The regulations for drug and biological product labeling expressly recognize the 
importance of diagnostic tests to the safe and effective use of these therapeutic products.  
According to the labeling regulations for drugs and biological products (21 CFR 201.56 and 57), 
product labeling must include information about (1) specific tests necessary for selection or 
monitoring of patients who need a drug; (2) dosage modifications in special patient populations 
(e.g., in groups defined by genetic characteristics); and (3) the identity of any laboratory test(s) 
helpful in following a patient’s response or in identifying possible adverse reactions. The 
labeling regulations identify labeling sections where such discussion is appropriate (e.g., 
Indications and Usage, Dosage and Administration, Contraindications, Warnings and 
Precautions, Use in Specific Populations).  For example: 
 
x If a drug or biological product has been shown to be safe and effective in only a certain 
patient population identified by a diagnostic test, the Indications and Usage section must 
clearly define the patient population in whom the drug is approved (21 CFR 
201.57(c)(2)(i)(B) and (C)).  
x If a diagnostic test is essential for monitoring either therapeutic or toxic effects, the type 
of test must be identified under Warnings and Precautions (21 CFR 201.57(c)(6)(iii)).   
 
Because it is important that the approved labeling for an IVD companion diagnostic device and 
its corresponding therapeutic product be complete and consistent, FDA makes the following 
clarifications.  
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x Ordinarily, information about the use of an IVD companion diagnostic device will be 
included in the labeling of its corresponding therapeutic product when the device meets 
the definition of an IVD companion diagnostic device (see Section III).  As already 
clarified in Section IV.B, there may be situations when information about an unapproved 
or uncleared IVD diagnostic device is included in the labeling of a therapeutic product. 
x When appropriate, the therapeutic product labeling should identify a type of FDA 
approved or cleared IVD companion diagnostic device (i.e., the intended use of the 
device), rather than a specific manufacturer’s IVD companion diagnostic device.  This 
will facilitate the development and use of more than one approved or cleared IVD 
companion diagnostic device of the type described in the labeling for the therapeutic 
product.     
x In cases, when an IVD companion diagnostic device is approved or cleared and is 
marketed after the therapeutic product is approved, the therapeutic product labeling 
should be updated to refer to the use of the IVD companion diagnostic device or type of 
IVD companion diagnostic device (21 CFR 201.56(a)(2)). 
 
B. IVD Companion Diagnostic Device Labeling 
 
The labeling for an in vitro diagnostic is required to specify the intended use of the diagnostic  
device (21 CFR 809.10(a)(2)).  Therefore, an IVD companion diagnostic device that is intended 
for use with a therapeutic product must specify the therapeutic product(s) for which it has been 
approved or cleared for use.  In some cases, if evidence is sufficient to conclude that the IVD 
companion diagnostic device is appropriate for use with a class of therapeutic products, the 
intended use/indications for use should name the therapeutic class, rather than each specific 
product within the class. 
 
When an IVD companion diagnostic device has been approved or cleared for use with a 
therapeutic product in one disease or setting, the IVD companion diagnostic device labeling 
should be expanded through approval or clearance of a new premarket submission (PMA or 
510(k) as appropriate) or PMA supplement if new or revised therapeutic product labeling 
becomes available that stipulates that the use of the IVD companion diagnostic device or type of 
IVD companion diagnostic device is essential for the safe and effective use of the therapeutic 
product in another disease or setting.   
 
When an IVD companion diagnostic device has been approved or cleared for use with one 
therapeutic product and evidence becomes available that use of the same device is essential for 
the safe and effective use of a different therapeutic product, the IVD companion diagnostic 
device labeling should be expanded through approval or clearance of a new premarket 
submission (PMA or 510(k) as appropriate) or PMA supplement (in accordance with Section IV, 
above) to include the new therapeutic product. Labeling of the therapeutic product should also be 
amended through submission of a supplement. 
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VI. Investigational Use  
 
All diagnostic devices used to make treatment decisions in a clinical trial of a therapeutic product 
will be considered investigational devices, unless employed for an intended use for which the 
device is already approved or cleared.  If used to make critical treatment decisions, such as 
patient selection, treatment assignment, or treatment arm, a diagnostic device generally will be 
considered a significant risk device under 21 CFR 812.3(m)(3) because it presents a potential for 
serious risk to the health, safety, or welfare of the subject, and the sponsor of the diagnostic 
device will be required to comply with the investigational device exemption (IDE) regulations 
that address significant risk devices.  In such cases, FDA will expect the sponsor to conduct the 
trial under full IDE regulations.11   
 
If a diagnostic device and a therapeutic product are to be studied together to support their 
respective approvals (or clearance as appropriate for the diagnostic device), both products can be 
studied in the same investigational study, if the study is conducted in a manner that meets both 
the requirements of the IDE regulations and the investigational new drug (IND) regulations (21 
CFR Part 312).   
 
Information about the planned use of an IVD companion diagnostic device and its use in clinical 
trials should be included in an investigational submission.  This information will help FDA 
understand and provide advice on how the IVD device will be used to enroll subjects into the 
trial(s) and how the test will be validated for use.  For therapeutic product INDs, the therapeutic 
product review center (Center for Drug Evaluation and Research or Center for Biologics 
Evaluation and Research (CBER)) will engage appropriate expertise from the diagnostic product 
review center (Center for Devices and Radiological Health or CBER), and joint advice will be 
provided to the sponsor.   
 
In addition, it will be helpful if both the IVD companion diagnostic device product sponsor and 
the therapeutic product sponsor submit information about the proposed IVD companion 
diagnostic device in a preIDE (a consultative submission designed to ensure that appropriate 
validation studies are planned and carried out) to the diagnostic review center.  This will enable a 
more focused and in-depth discussion about the validation of the IVD companion diagnostic 
device and will aid in planning for a device PMA or 510(k) that is complete and timely.  When 
appropriate, expertise from the relevant therapeutic review center will be included in the 
diagnostic review center meetings. 
 
FDA strongly encourages sponsors considering developing either of the products discussed in 
this guidance to request a meeting with both relevant device and therapeutic product review 
divisions as early in development as possible. 
11 Alternatively, if the IVD companion diagnostic device and therapeutic product are considered a combination 
product, FDA will expect the investigational device to be investigated under the IND for the therapeutic product 
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